NOVO NORDISK A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 927.3 DKK | +1.13% |
|
-0.16% | +32.83% |
| May. 31 | Zealand Pharma Secures EU Panel Backing for Severe Hypoglycemia Treatment | MT |
| May. 30 | Danish Government Implements Stricter Subsidy Rules for Diabetes Drugs | MT |
ETFs positioned on Novo Nordisk A/S
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 21.31% | 200 M€ | +16.70% | ||
| 10.45% | 5 M€ | +15.85% | ||
| 5.40% | 17 M€ | +6.09% | - | |
| 4.67% | 88 M€ | +10.37% | - | |
| 3.95% | 4 M€ | -.--% | - | |
| 3.91% | 5 M€ | +10.09% | - | |
| 3.91% | 14 M€ | +5.66% | - | |
| 3.78% | 6 M€ | -.--% | ||
| 3.09% | 12 M€ | +15.09% | - | |
| 3.02% | 6 M€ | -.--% | - | |
| 2.87% | 29 M€ | +8.37% | - | |
| 2.53% | 3,859 M€ | +18.82% | - | |
| 2.53% | 469 M€ | -2.05% | ||
| 2.22% | 3 M€ | +9.95% | - | |
| 1.91% | 2 M€ | -.--% | - | |
| 1.91% | 2 M€ | +9.19% | - | |
| 1.67% | 10 M€ | -3.35% | - | |
| 1.60% | 10 M€ | +6.14% | - | |
| 1.31% | 253 M€ | +5.88% | ||
| 1.30% | 48 M€ | +9.22% | ||
| 1.04% | 276 M€ | +11.40% | - | |
| 1.03% | 7 M€ | +5.36% | - | |
| 0.89% | 1,083 M€ | +4.80% | ||
| 0.79% | 284 M€ | -.--% | ||
| 0.76% | 786 M€ | -.--% | ||
| 0.76% | 23 M€ | -.--% | - | |
| 0.75% | 206 M€ | -.--% | ||
| 0.70% | 7 M€ | +0.11% | - | |
| 0.64% | 264 M€ | -.--% | - | |
| 0.64% | 187 M€ | +9.30% | - | |
| 0.64% | 477 M€ | +11.68% | ||
| 0.57% | 727 M€ | +7.40% |
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
927.3
DKK
Average target price
917.2
DKK
Spread / Average Target
-1.09%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +32.83% | 598B | |
| +40.73% | 739B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| -5.52% | 206B | |
| +6.17% | 164B | |
| -0.45% | 162B | |
| -.--% | 122B |
- Stock Market
- Equities
- NOVO B Stock
- Funds and ETFs Novo Nordisk A/S
